Long term hematopoeitic damage after chemotherapy and cytokine

Renee, V Gardner

doi:10.2741/gardner

Cited by 13 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To make this robust and surge inflammatory response, individuals should have an effective immune system. However, the negative impact of CT on the immune system is well known for years [34]. Furthermore, after the mitigation of immune functions by CT, recovery of the immune system might take a long time [35].…”

Section: Discussionmentioning

confidence: 99%

A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19

Yekedüz

Utkan

Ürün

2020

European Journal of Cancer

107

View full text Add to dashboard Cite

Background The COVID-19 pandemic hit all over the world and cancer patients are more vulnerable for COVID-19. Mortality rate may increase up to 25% in solid malignancies. In parallel to increased mortality rates among cancer patients, safety concerns regarding cancer treatment has increased over time. However, there were contradictory results for the cancer treatment during pandemic. In this study, we assessed the effect of cancer treatment on the severity of COVID-19. Methods The MEDLINE database was searched on September 01, 2020. Primary endpoints were severe disease and death in the cancer patients treated within the last 30 days before COVID-19 diagnosis. Quality of included studies were assessed by New Castle-Ottawa Scale. Generic inverse variance method was used to calculate odds ratios (ORs) for each outcome. Results Sixteen studies were included for this meta-analysis. Chemotherapy within the last thirty days before COVID-19 diagnosis increased the risk of death in cancer patients after adjusting for confounding variables (OR: 1.85; 95% CI:1.26-2.71). However, severe COVID-19 risk did not increase. Furthermore, targeted therapies, immunotherapy, surgery, and radiotherapy did not increase the severe disease and death risk in cancer patients with COVID-19. Conclusion Chemotherapy increased the risk of death from COVID-19 in cancer patients. However, there was no safety concern for immunotherapy, targeted therapies, surgery, and radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19

Yekedüz

Utkan

Ürün

2020

European Journal of Cancer

107

View full text Add to dashboard Cite

show abstract

“…One of the common side effects of chemotherapy is myelosuppression, that can lead to the exhaustion of hematopoietic stem and progenitor cells (HSPCs; refs. [56][57][58].…”

Section: Cdk4/6-independent Tumors-host Protectionmentioning

confidence: 99%

Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows

Roberts

Kumarasamy

Witkiewicz

et al. 2020

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Cyclin-dependent kinases 4 and 6 (CDK4/6) have emerged as important therapeutic targets. Pharmacologic inhibitors of these kinases function to inhibit cell-cycle progression and exert other important effects on the tumor and host environment. Because of their impact on the cell cycle, CDK4/6 inhibitors (CDK4/6i) have been hypothesized to antagonize the antitumor effects of cytotoxic chemotherapy in tumors that are CDK4/6 dependent. However, there are multiple preclinical studies that illustrate potent cooper-ation between CDK4/6i and chemotherapy. Furthermore, the combination of CDK4/6i and chemotherapy is being tested in clinical trials to both enhance antitumor efficacy and limit toxicity. Exploitation of the noncanonical effects of CDK4/6i could also provide an impetus for future studies in combination with chemotherapy. Thus, while seemingly mutually exclusive mechanisms are at play, the combination of CDK4/6 inhibition and chemotherapy could exemplify rational medicine.

show abstract

“…We selected immunological biomarkers because (a) changes in these markers are related to stress (Graham, Christian, & Kiecolt-Glaser, 2006), (b) they have extensive links with symptoms of cancer and cancer treatment (detailed below), and (c) they are easily obtainable. Several biomarkers have been correlated with both physical and psychological symptoms experienced by cancer patients on and off treatment (Gardner, 1999;Kang et al, 2009;van der Most, Currie, Robinson, & Lake, 2006). Changes in immune function and associated biomarker expression in cancer survivors resulting from psychological distress may directly or indirectly affect survival outcomes (Andersen et al, 2007;Sephton et al, 2009).…”

mentioning

confidence: 99%

Baseline Immune Biomarkers as Predictors of MBSR(BC) Treatment Success in Off-Treatment Breast Cancer Patients

Reich

Lengacher

Kip

et al. 2014

Biological Research For Nursing

View full text Add to dashboard Cite

Researchers focused on patient-centered medicine are increasingly trying to identify baseline factors that predict treatment success. Because the quantity and function of lymphocyte subsets change during stress, we hypothesized that these subsets would serve as stress markers and therefore predict which breast cancer patients would benefit most from mindfulness-based stress reduction (MBSR)-facilitated stress relief. The purpose of this study was to assess whether baseline biomarker levels predicted symptom improvement following an MBSR intervention for breast cancer survivors (MBSR[BC]). This randomized controlled trial involved 41 patients assigned to either an MBSR(BC) intervention group or a no-treatment control group. Biomarkers were assessed at baseline, and symptom change was assessed 6 weeks later. Biomarkers included common lymphocyte subsets in the peripheral blood as well as the ability of T cells to become activated and secrete cytokines in response to stimulation with mitogens. Spearman correlations were used to identify univariate relationships between baseline biomarkers and 6-week improvement of symptoms. Next, backward elimination regression models were used to identify the strongest predictors from the univariate analyses. Multiple baseline biomarkers were significantly positively related to 6-week symptom improvement. The regression models identified B-lymphocytes and interferon-γ as the strongest predictors of gastrointestinal improvement (p < .01), +CD4+CD8 as the strongest predictor of cognitive/psychological (CP) improvement (p = .02), and lymphocytes and interleukin (IL)-4 as the strongest predictors of fatigue improvement (p < .01). These results provide preliminary evidence of the potential to use baseline biomarkers as predictors to identify the patients likely to benefit from this intervention.

show abstract

Long term hematopoeitic damage after chemotherapy and cytokine

Abstract: Introduction 3. The Targeted Cell 4. Pathophysiology Explored 4.1. Chemotherapy Effect on Stroma 4.2. Ineffective DNA Repair 4.3. Decreased Responsiveness to Normal Growth Stimuli 4.4. Accelerated Cycling at the Expense of Self-renewal 5. Chemoprotection 6. Acknowledgement 7. References

Cited by 13 publications

References 29 publications

A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19

A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19

Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows

Baseline Immune Biomarkers as Predictors of MBSR(BC) Treatment Success in Off-Treatment Breast Cancer Patients

Contact Info

Product

Resources

About